Novo Nordisk's New Weight Loss Drug Shows Ominous Psychiatric Side Effects
Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to its trial results, it has some pretty freaky side effects. As Fierce Biotech reports,
Novo Nordisk Sinks on Obesity Drug Study's Disappointing Results
Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment showed less effectiveness in higher doses.
Novo Nordisk stock tumbled over the latest results for its experimental weight loss pill
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that works differently than its already-popular weight loss drug Wegovy.
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial
Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.
Novo Shares Fall on Safety Data for New Weight-Loss Drug
Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation weight-loss drugs.
Novo Nordisk shares drop nearly 5% on disappointing obesity pill data
Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.
Viking, Structure, Terns benefiting from disappointing Novo Nordisk weight loss data
Structure Therapeutics (NASDAQ:GPCR), and Terns Pharmaceuticals (NASDAQ:TERN), which are all developing oral pills as weight loss treatments, are trading higher Friday following disappointing results from a rival Novo Nordisk (NVO) drug.
How Ozempic Works—and What’s Still a Mystery
Few medications have become as popular and culturally relevant as Ozempic has, but how exactly do it and similar drugs affect ...
Sanders says generic drugmakers could sell Novo Nordisk Ozempic for less than $100
Senator Sanders (I-Vt.) says CEOs of generic drugmakers are willing to sell Novo Nordisk’s (NVO) blockbuster obesity medicine ...
NJBIZ1d
Novo Nordisk expects Ozempic in next round of Medicare price talks
In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...
Novo Says Ozempic ‘Very Likely’ Target for Next US Price Cut
Ozempic, the blockbuster diabetes shot made by Novo Nordisk A/S, is “very likely” to be one of the next drugs targeted for a ...
Novo says Ozempic 'very likely' to be on 2027 Medicare negotiation list, Bloomberg News reports
Danish drugmaker Novo Nordisk expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of ...
Novo Nordisk: The Street Is Not Seeing The Growth Acceleration Potential
Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...
Cheap Ozempic is coming: Cost could soon be slashed for millions of Americans, drugmaker confirms — here’s how
This news of Ozempic price cuts comes on the heels, or tablet, of Novo Nordisk developing a weight loss pill that mirrors the ...
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.